Since the introduction of anti-TNF inhibitors as the first approved treatments for IBD, the roles of the IL-12/Th1 and IL-23/Th17 pathways in IBD pathogenesis have become increasingly recognized. This evidence concerns the gene TNF and inflammatory bowel disease.